Melanoma is the most dangerous type of skin cancer. It accounts for a small fraction of all skin cancer cases but is responsible for the majority of skin cancer deaths, with an estimated 8,430 deaths projected in the United States in 2025 alone. What makes melanoma uniquely lethal is its ability to spread beyond the skin to distant organs, including the brain, lungs, and liver.
Why Melanoma Is Far More Lethal Than Other Skin Cancers
The three main types of skin cancer are basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. BCC and SCC are by far the most common cancers in the United States, but they rarely kill. The age-adjusted death rate for SCC is roughly 1 per 100,000 people per year, and BCC carries no measurable increase in mortality risk at all. Patients with SCC do have about a 25% higher all-cause mortality rate than the general population, but that figure partly reflects the fact that SCC tends to affect older people who already have other health conditions.
Melanoma is a different story. It develops in the pigment-producing cells of the skin, and unlike BCC and SCC, it has a strong tendency to invade deeper tissue and enter the lymphatic system and bloodstream. Once it reaches distant organs, survival drops sharply. The five-year survival rate for localized melanoma (caught before it spreads) is above 99%. When it has spread to nearby lymph nodes, that drops to 76%. When it reaches distant sites, only about 35% of patients survive five years.
How Melanoma Spreads Through the Body
Melanoma cells have a remarkable biological trick that helps them survive the journey from your skin to distant organs. Research from UT Southwestern found that melanoma cells traveling through the lymphatic system absorb high levels of a fatty acid called oleic acid. This oleic acid gets built into the cells’ outer membranes, shielding them from a type of cell death caused by oxidative stress. Melanoma cells in the bloodstream are normally vulnerable to this kind of damage, but cells that first pass through the lymph nodes become, as the lead researcher put it, “bulletproof” against it. They survive in the blood and successfully seed new tumors at distant sites. This helps explain why melanoma that reaches the lymph nodes is so much more dangerous than melanoma that stays localized.
Not All Melanomas Are Equal
Melanoma itself comes in several subtypes, and they don’t all behave the same way. Superficial spreading melanoma is the most common form and tends to grow outward across the skin’s surface for months or even years before it invades deeper layers. Patients typically notice these over a period of about nine months before diagnosis.
Nodular melanoma is considerably more aggressive. It grows downward into the skin almost immediately, with a typical onset-to-diagnosis window of only about five months. Its cell division rate is more than double that of superficial spreading melanoma. Because it penetrates deeper tissue faster, nodular melanoma is more likely to reach the lymphatic system and metastasize before a person seeks medical attention.
A Rarer Cancer That’s Even More Aggressive
While melanoma is correctly identified as the most dangerous common skin cancer, it’s worth knowing about Merkel cell carcinoma (MCC), a rare cancer of the skin’s nerve-related cells. MCC is significantly more lethal than melanoma on a case-by-case basis. A study using California Cancer Registry data found that the 10-year survival rate for MCC was just 17.7%, compared to 61.3% for melanoma. MCC also has a higher rate of spreading to nearby lymph nodes. However, because MCC is so uncommon, melanoma kills far more people in total each year.
What Raises Your Risk
Ultraviolet radiation is the single biggest environmental driver of melanoma. An estimated 60 to 70% of melanomas are caused by UV exposure, from both sunlight and artificial sources like tanning beds. Childhood sun exposure is particularly damaging. Some studies suggest that childhood sunburns can double the lifetime risk of melanoma, and indoor tanning before age 30 increases melanoma risk by 75%.
Genetics play a meaningful role as well. About 3 to 15% of melanomas arise from inherited genetic predispositions. People with red hair and freckles carry a mutation that prevents their skin from producing the more protective type of melanin, leaving them more sensitive to UV damage and at higher melanoma risk regardless of their actual skin tone. Certain gene mutations found in melanoma cells are not caused by UV at all. One such mutation appears in roughly 60% of all melanomas and drives cell growth independently of sun exposure.
How to Spot Melanoma Early
Because the difference between localized and distant melanoma is the difference between a 99% and 35% survival rate, early detection matters enormously. The standard screening tool is the ABCDE rule, which describes what to look for in a mole or skin spot:
- Asymmetry: one half of the mole doesn’t match the other
- Border: the edges are ragged, notched, or blurred rather than smooth
- Color: uneven coloring, with mixtures of black, brown, tan, or patches of white, red, pink, or blue
- Diameter: larger than about 6 millimeters (roughly the size of a pencil eraser), though melanomas can be smaller
- Evolving: the mole has changed in size, shape, or color over recent weeks or months
Any spot that fits one or more of these criteria deserves a closer look from a dermatologist. Nodular melanomas, however, can be tricky because they sometimes appear as small, uniform, dome-shaped bumps that don’t follow the typical ABCDE pattern. Any new, rapidly growing bump on the skin that bleeds or doesn’t heal warrants attention.
Treatment Has Improved Dramatically
The outlook for advanced melanoma has transformed over the past decade. Before modern immunotherapy, patients with inoperable stage IV melanoma had a median survival of just 6 to 9 months. Today, combination immunotherapy using two types of immune checkpoint inhibitors has pushed median survival to nearly 6 years for advanced disease. These treatments work by removing the molecular “brakes” that melanoma uses to hide from the immune system, allowing the body’s own defenses to attack the cancer.
That said, advanced melanoma remains a serious diagnosis, and the survival gap between early and late detection is still enormous. The overall five-year survival rate across all stages is 95%, which reflects the fact that most melanomas are caught early. Death rates from melanoma have been falling by an average of 2.2% per year over the past decade, driven by both earlier diagnosis and better treatment options.